When your patient’s seriously bleeding or surgery can’t be delayed, what could the next generation of factor Xa inhibitor reversal therapies offer?

Join experts Alex Spyropoulos, Lana Castellucci, and Gabe Fontaine as they break down:

• Why more treatment options are needed

• Different paths to restoring clotting

• What PCC trials tell us

• VMX-C001: A distinct approach under investigation

• Why controlling bleeding is only part of the story

Tune in and subscribe to Clot, Clot, Who’s There? for more expert conversations in thrombosis, hemostasis, and vascular medicine.

Episode Chapters

0:00 Introduction and gaps in current treatment

7:35 Investigational reversal agents

13:30 PCC data overview

18:20 The EQUILIBRIX-S trial

24:01 Patient-important outcomes and key takeaways

Thank you to our sponsor, VarmX, for their generous support of this podcast episode. 

Check out the companion learning course, No Time To Wait: Urgent Situations in Patients on Factor Xa Inhibitors, here.